An Open, Multi-center, Phase I Clinical Study on the Safety and Efficacy of HGI-001 Injection in Patients with Transfusion-Dependent β-thalassaemia
Latest Information Update: 28 Oct 2024
Price :
$35 *
At a glance
- Drugs HGI 001 (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions; Therapeutic Use
- 28 Oct 2024 New trial record